Singapore's Ion Investments Buys Another 10% Stake In Korea's Celltrion In Anticipation of 2012 Biosimilars Launch
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Celltrion, Inc. said Sept. 1 that Singapore's Ion Investments B.V., a wholly-owned subsidiary of Temasek Holdings Pte. Ltd., purchased 10% of the outstanding shares of Celltrion Healthcare Co., Celltrion's global distribution and marketing arm, increasing the investor's share in the Korean company
You may also be interested in...
Celltrion Nearly Triples Production Capability For Biosimilars In Anticipation Of Global Launches
SEOUL - South Korea's biosimilar front-runner Celltrion, Inc. will begin production at a new 90,000-liter manufacturing plant Oct. 5 located at its main plant in Incheon City
Celltrion Nearly Triples Production Capability For Biosimilars In Anticipation Of Global Launches
SEOUL - South Korea's biosimilar front-runner Celltrion, Inc. will begin production at a new 90,000-liter manufacturing plant Oct. 5 located at its main plant in Incheon City
Korea's Celltrion Sees Growth Trend Continue On Strength Of Biosimilar Validation Batch Orders
SEOUL - Celltrion, Inc. retained upward momentum in its earnings for the second quarter thanks to continued strong shipment of validation batches for biosimilars of Roche's breast cancer agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis drug Remicade (infliximab)